Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis (MS-IL2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02424396
Recruitment Status : Completed
First Posted : April 23, 2015
Last Update Posted : November 9, 2020
Sponsor:
Collaborator:
Fondation ARSEP/AFM
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the capacity to stimulate regulatory T cells (Tregs). At low dose, Il-2 tips the Treg/Teff balance towards Tregs. Recently, it has been shown that Tregs of MS patients have reduced proliferative potential. MS-IL2 will assess the safety and biological efficacy of low-dose IL2 as a Treg inducer in a Relapsing-Remitting Multiple Sclerosis (RRMS), with the aim to stimulate Treg and define potential clinical benefits

Condition or disease Intervention/treatment Phase
Relapsing Remitting Multiple Sclerosis Drug: IL2 Drug: Placebo Phase 2

Detailed Description:

In MS-IL2, 30 RRMS patients will be treated in a randomized, double-blind, placebo controlled clinical trial. IL-2 will be administered first as an induction course of IL-2 or placebo each day for 5 days, followed by a maintenance course at the same dose or placebo every two weeks over 6 months.

The primary efficacy criteria will be the % change from baseline in Treg at day-5, which is indicative of the biological response to IL-2.

The secondary efficacy criteria will be (i) the maintenance of regulatory T cells during the 6 months of treatment with IL-2 vs. placebo and (ii) the stabilization or regression of the disease as determined by disease activity parameters assessed by MRI (cumulative number of new lesions in T1 enhanced by gadolinium after 6 months) in the groups treated with IL-2 compared to placebo.

Expected impact: MS-IL2 will define which patient respond to IL2 and which doses prevent relapses in RRMS. In addition, the deep phenomics studies will further provide the foundation for a clinical phase II to define clinical efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study
Actual Study Start Date : June 13, 2016
Actual Primary Completion Date : October 11, 2019
Actual Study Completion Date : June 15, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1 : IL2
Interleukin-2 (ILT-101)
Drug: IL2
Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2

Placebo Comparator: 2 : Placebo
Placebo
Drug: Placebo



Primary Outcome Measures :
  1. Treg response to low dose IL2 induction course period, expressed as % of total CD4 cells [ Time Frame: at day5 ]

Secondary Outcome Measures :
  1. Change in Treg percentage on D15 after induction (D1-D5) compared to baseline [ Time Frame: at day15 ]
  2. Change in Treg percentage from D15 to M6 compared to baseline [ Time Frame: Day 15 to Day 169 ]
  3. The cumulative number of new lesions enhanced by Gd+ (Sum of Gd + lesions on T1 MRI on M2, M4 and M6) [ Time Frame: Day 57, Day 113 and Day 169 ]
  4. Frequency of patients free of Gd+ lesions at M6 [ Time Frame: Day 169 ]
  5. The cumulative number of new T2 lesions [ Time Frame: Day 169 ]
  6. Annual relapse rate (number of relapses observed over a 6 month period) [ Time Frame: Day 169 ]
  7. % of patients with flare [ Time Frame: Day 169 ]
  8. % of disease free patient i.e % of patient with no clinical symptoms and no activity on MRI [ Time Frame: Day 169 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18-65 years old ;
  • Male and Female;
  • Presenting relapsing remitting multiple sclerosis as determined by revised McDonald criteria (2010) ;
  • On MRI : 1) Presenting 1-2 lesions enhanced by gadolinium (Gd+) (T1) without clinical expression of the disease clinique upon inclusion or 6 months prior to inclusion or 2) presenting one new lesion T2
  • Expanded Disability Status Scale (EDSS) score comprised between 0 and 6;
  • No flare (with or without any corticosteroid therapy) for the past 2 months
  • Under β-Interferon treatment for ≥ 6 months ; or any other first-line treatment of the Relapsing-Remitting Multiple Sclerosis (RRMS): Dimethyl fumarate or teriflunomide treatment for ≥ 6 months or glatiramer acetate for ≥ 9 months
  • For women of childbearing age, contraception for more than 2 weeks upon confirmation of inclusion criteria and negative Beta HCG on inclusion visit (D-30 to D-7);
  • Patient informed consent should be signed by the patient and investigator before performing any clinical examination required for the study.
  • Affiliation to the French Social Security Regimen

Exclusion Criteria:

  • Number of lesions enhanced by gadolinium (Gd+) on MRI in T1 > 2 upon inclusion;
  • Known intolerance to IL2 (see SPC):

    • Hypersensibility to active substance or one of the excipients ;
    • Signs of evolving infection requiring treatment
    • Other clinically significant chronic disorders (beside RR-MS)
    • History of organ allograft
  • Administration of a non-authorized treatment; bolus of corticosteroids in the last 2 months, or treatment with cyclophosphamide, mitoxantrone, or rituximab in the last 6 months;
  • Heart failure (≥ grade III NYHA), renal insufficiency, or hepatic insufficiency (transaminase>5N), or lung failure
  • White blood cell count <3000 /mm3, lymphocytes< 1000 /mm3, platelets <150 000 /mm3
  • Poor venous access not allowing repeated blood tests
  • Vaccination with live attenuated virus in the months preceding the inclusion or planned during the study
  • Surgery with general anaesthesia during the last 2 months or surgery planned during the study
  • Participation in other biomedical research in the last one month or planned during the study
  • Concomitant psychiatric disease or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give informed consent
  • Cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma)
  • Pregnant or lactating women;
  • Men and women of childbearing potential without effective contraception for the duration of treatment
  • Patients under a measure of legal protection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02424396


Locations
Layout table for location information
France
Centre d'investigation Clinique - Pitié salpêtrière
Paris, France, 75013
Centre d'investigation clinique Biothérapie Immunologie (CIC-BTi) - Groupe Hospitalier Pitié-Salpêtrière - AP-HP
Paris, France, 75013
Département des maladies du système nerveux et Centre d'investigation clinique - Groupe Hospitalier Pitié-Salpêtrière - AP-HP
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Fondation ARSEP/AFM
Investigators
Layout table for investigator information
Principal Investigator: David Klatzmann Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02424396    
Other Study ID Numbers: P130102
2014-000088-82 ( Other Identifier: EudractCT )
First Posted: April 23, 2015    Key Record Dates
Last Update Posted: November 9, 2020
Last Verified: November 2020
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Interleukin 2, IL2
Relapsing Remitting Multiple Sclerosis
Autoimmune diseases
Regulatory T cells, Tregs
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases